PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
| dc.rights.license | open | en_US |
| dc.contributor.author | ITALIANO, A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | D'ANGELO, S. | |
| dc.date.accessioned | 2021-01-27T08:31:59Z | |
| dc.date.available | 2021-01-27T08:31:59Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1756-8722 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26043 | |
| dc.description.abstractEn | Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data related to their activity in soft-tissue sarcomas (STS) are scarce.We performed a pooled analysis of clinical trials investigating a PD1 or PD-L1 antagonist in patients with advanced STS. Three hundred eighty-four patients were included in the pooled analysis; of those, 153 (39.8%) received a PD1/PD-L1 antagonist as a single agent. In patients treated with anti-PD1/PDL1 as a single agent, the overall response rate (ORR) and non-progression rate (NPR) were 15.1% and 58.5% respectively. In patients treated with a combination regimen, the ORR and NPR were 13.4% and 55.8% respectively. Analysis by histological subtype revealed that patients with alveolar soft part sarcoma and undifferentiated pleomorphic sarcoma exhibited the highest response rates and leiomyosarcoma the lowest. PD-L1 expression rate was low and inconsistently associated with objective response.PD-1/PD-L1 antagonists have limited activity in unselected STS. Future studies should implement histology and immune-based stratification of STS in their design as well as sequential blood and tissue sampling to better understand the mechanisms of resistance and response given sarcomas inherent heterogeneity. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject | EPICENE | |
| dc.title.en | PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials | |
| dc.title.alternative | J Hematol Oncol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s13045-020-00891-5 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32430039 | en_US |
| bordeaux.journal | Journal of Hematology and Oncology | en_US |
| bordeaux.page | 55 | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | EPICENE_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03122472 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-01-27T08:32:02Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Hematology%20and%20Oncology&rft.date=2020&rft.volume=13&rft.issue=1&rft.spage=55&rft.epage=55&rft.eissn=1756-8722&rft.issn=1756-8722&rft.au=ITALIANO,%20A.&BELLERA,%20Carine&D'ANGELO,%20S.&rft.genre=article |
